Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Non-penetrating deep sclerectomy with EX-PRESS R-50 drainage implantation in glaucoma surgical treatment

Poster Details

First Author: K.Pershin RUSSIA

Co Author(s):    N. Pashinova   A. Tsygankov   G. Solovyeva   L. Batalina   E. Gurmizov   V. Kashnikov     

Abstract Details


Analysis of the medium- and long-term results of the mini-shunt Ex-Press implantation in glaucoma treatment


Eximer eye center


Non-penetrating deep sclerectomy with the mini-shunt Ex-PRESS R-50 implantation was performed in 176 eyes of 161 patients with uncontrolled and/or refractory to drug therapy glaucoma between 2011 and 2014. A standard planned ophthalmologic examination was performed for all patients prior to surgery and within 1 day, 7 days, 1, 2, 3, 6, 12, 18, 24 and 36 months after implantation of drainage. In a number of patients, examinations were also performed in 48 (n=44) and 60 (n=21) months after the operation. In addition, patients were divided into group I ("phakic" glaucoma, n = 53) and group II (pseudophakic glaucoma, n=108)


Mean follow-up period was 43.7±2.9 months. Mean age of patients at the time of surgery was 72.4±9.6 years. IOP decrease compared with preoperative values at the follow-up period of 24 months, the IOP decreased to 15.3±6.6 mm Hg, at follow-up of 36 months to 17.5±6.8 mm Hg. (45.8%). In 44 patients (27.3%) 48 months later, the level of the "success" was exceeded - 22.4±8.0 mmHg. In the period of 60 months after the operation,mean level of IOP dynamics in 21 patients (13%) was 26.1±8.2 mm Hg. There was a significant decrease in the number drugs.


Implantation of the ExPress mini-shunt is indicated in complicated cases of refractory glaucoma with ineffectiveness of previous interventions or inability to compensate intraocular pressure at the maximum possible mode of antiglaucoma drugs.

Financial Disclosure:


Back to Poster listing